104 related articles for article (PubMed ID: 35596117)
1. First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients.
Ort M; Dingemanse J; Hsin CH; Richard M; Huehn E; Sabattini G; van de Wetering J; Kornberger R; van den Anker J; Kaufmann P
Basic Clin Pharmacol Toxicol; 2022 Aug; 131(2):114-128. PubMed ID: 35596117
[TBL] [Abstract][Full Text] [Related]
2. Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a
Anliker-Ort M; Dingemanse J; Farine H; Groenen P; Kornberger R; van den Anker J; Kaufmann P
Br J Clin Pharmacol; 2023 Jan; 89(1):380-389. PubMed ID: 36000981
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
4. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.
Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
Br J Clin Pharmacol; 2020 Jul; 86(7):1377-1386. PubMed ID: 32067262
[TBL] [Abstract][Full Text] [Related]
6. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
Richard M; Kaufmann P; Kornberger R; Dingemanse J
Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study.
Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Boof ML; Géhin M; Voors-Pette C; Hsin CH; Sippel V; Strasser DS; Dingemanse J
Br J Clin Pharmacol; 2024 Feb; 90(2):588-599. PubMed ID: 37752659
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
Fossler MJ; Schmith V; Greene SA; Lohmer L; Kramer MS; Arscott K; James IE; Demitrack MA
CNS Drugs; 2020 Aug; 34(8):853-865. PubMed ID: 32676977
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.
Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110166. PubMed ID: 33159976
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T
Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study.
Lee DY; Lee MJ; Ryu C; Lee H; Brooks A
Pharmacol Res Perspect; 2023 Feb; 11(1):e01040. PubMed ID: 36734627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]